Analyst Price Target is $20.50
▲ +217.83% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Aura Biosciences in the last 3 months. The average price target is $20.50, with a high forecast of $22.00 and a low forecast of $19.00. The average price target represents a 217.83% upside from the last price of $6.45.
Current Consensus is
Moderate Buy
The current consensus among 7 investment analysts is to moderate buy stock in Aura Biosciences. This rating has held steady since September 2025, when it changed from a Buy consensus rating.
Aura Biosciences, Inc., a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates. Its lead candidate is bel-sar, which is in late-stage clinical development for the treatment of patients with primary choroidal melanoma and other ocular oncology indications, as well as in early-stage clinical development in bladder cancer. The company also focuses on assessing the safety and efficacy of bel-sar in treating a range of other solid tumors, including bladder cancer as an alternative to bacillus calmetteguérin therapy. Aura Biosciences, Inc. was incorporated in 2009 and is headquartered in Boston, Massachusetts.
Read More
